WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016057398) NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/057398 International Application No.: PCT/US2015/054011
Publication Date: 14.04.2016 International Filing Date: 05.10.2015
IPC:
A61K 35/00 (2006.01) ,A61K 31/166 (2006.01) ,A61K 31/4745 (2006.01) ,A61P 35/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide
166
having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4738
ortho- or peri-condensed with heterocyclic ring systems
4745
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
04
specific for metastasis
Applicants: IMMUNOMEDICS, INC.[US/US]; 300 American Road Morris Plains, New Jersey 07950, US
Inventors: GOLDENBERG, David M.; US
Agent: NAKASHIMA, Richard, A.; US
Priority Data:
62/060,85807.10.2014US
Title (EN) NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES
(FR) UTILISATION NÉOADJUVANTE DE CONJUGUÉS ANTICORPS-MÉDICAMENTS
Abstract:
(EN) The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).
(FR) La présente invention concerne des méthodes et des compositions améliorées destinées à une utilisation néoadjuvante de conjugués anticorps-médicaments (ADC) en thérapie du cancer, de préférence des ADC comprenant une anthracycline ou une camptothécine, de préférence encore une SN-38 ou une pro-2-pyrrolinodoxorubicine (P2PDox). L'ADC est administré sous la forme d'un néoadjuvant, avant le traitement avec une thérapie anticancéreuse standard telle qu'une chirurgie, une radiothérapie, une chimiothérapie, ou une immunothérapie. L'utilisation néoadjuvante de l'ADC améliore sensiblement l'efficacité de la thérapie anticancéreuse standard et peut réduire une tumeur primaire ou éliminer des micrométastases. Dans la plupart des modes de réalisation préférés, l'utilisation néoadjuvante d'ADC en association avec une thérapie anticancéreuse standard réussit à traiter les cancers qui sont résistants à des traitements standard, tels qu'un cancer du sein triple négatif (TNBC).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)